possible link between Actos (pioglitazone) and bladder cancer

October 2010

Please see updated FDA information concerning the risk of bladder cancer with Actos

First Avandia and heart attacks, now FDA is looking into a possible link between Actos (pioglitazone) and bladder cancer.

This is not entirely new. Early analysis of a new study MIGHT reinforce weak findings from older studies. Don't jump to conclusions...none of the studies actually show that Actos increases the risk of bladder cancer.

Take this as just one more reason to think twice before recommending EITHER Actos or Avandia as first choice drugs.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter membership benefits include:

  • 12 issues every year — what you need to know and do, right now
  • Quick, practical reference charts and tools
  • Comprehensive CE library to meet license renewal and state requirements
  • Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
  • Plus much more!

Choose the right tier for your needs today.

Already a subscriber? Log in

Volume pricing available. Get a quote